Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Halozyme Therapeutics Inc. buy Benchmark Co.

Halozyme Therapeutics Inc.
Start price
€36.23
16.04.24 / 50%
Target price
€46.98
16.04.25
Performance (%)
43.42%
End price
€51.96
17.04.25
Summary
This prediction ended on 17.04.25 with a price of €51.96. The BUY prediction by Benchmark_Co_ for Halozyme Therapeutics Inc. saw massive gains of 43.42%. Benchmark_Co_ has a follow-up prediction for Halozyme Therapeutics Inc. where he still thinks Halozyme Therapeutics Inc. is a Buy. Benchmark_Co_ has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Halozyme Therapeutics Inc. 8.607% 8.607% 50.113%
iShares Core DAX® -1,28 % 4,21 % 7,08 %
iShares Nasdaq 100 -3,34 % -1,74 % 26,18 %
iShares Nikkei 225® -4,29 % -1,62 % 44,32 %
iShares S&P 500 -2,31 % -0,10 % 20,82 %

Comments by Benchmark_Co_ for this prediction

In the thread Halozyme Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) 43.42%
Target price 46.975
Change
Ends at 16.04.25

Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat

Benchmark Co. 
0
Report Share
16.04.24
In the thread Trading Halozyme Therapeutics Inc.
Prediction Buy
Perf. (%) 43.42%
Target price 46.975
Change
Ends at 16.04.25

Die von Benchmark_Co_ gewählte maximale Laufzeit wurde überschritten

Benchmark Co. 
0
Report Share
17.04.25

Current prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€66.40
24.09.25
€76.27
24.09.26
39.49%
21.08.26

Benchmark Co. 
24.09.25 50%

Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€68.12
21.07.26
-
21.07.27
35.97%
21.08.26

Benchmark Co. 
21.07.26 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€59.58
03.06.26
-
03.06.27
55.45%
21.08.26

Benchmark Co. 
03.06.26 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€60.94
19.02.26
€76.30
19.02.27
51.99%
21.08.26

Benchmark Co. 
19.02.26 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€64.40
03.02.26
-
03.02.27
43.82%
21.08.26

Benchmark Co. 
03.02.26 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€54.68
20.02.25
€71.72
20.02.26
8.56%
21.02.26

Benchmark Co. 
20.02.25 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€49.87
08.08.24
€55.00
08.08.25
10.25%
09.08.25

Benchmark Co. 
08.08.24 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€48.68
25.06.24
€56.00
25.06.25
-7.99%
26.06.25

Benchmark Co. 
25.06.24 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€31.35
19.01.24
€45.94
19.01.25
69.19%
20.01.25

Benchmark Co. 
19.01.24 50%
buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€33.23
20.10.23
€47.17
20.10.24
45.44%
21.10.24

Benchmark Co. 
20.10.23 50%